Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme
This study is no longer recruiting patients.
Sponsored by: | EORTC Early Clinical Studies Group |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have recurrent glioblastoma multiforme.
Condition | Treatment or Intervention | Phase |
---|---|---|
recurrent adult brain tumor adult glioblastoma multiforme |
Drug: acridine carboxamide |
Phase II |
MedlinePlus related topics: Brain Cancer; Cancer; Cancer Alternative Therapy
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of Acridine Carboxamide in Patients With Recurrent Glioblastoma Multiforme
Study start: October 1999
OBJECTIVES: I. Determine the efficacy acridine carboxzmide in terms of objective response rate and response duration in patients with glioblastoma multiforme.
II. Determine the toxicities of this treatment regimen in this patient population.
PROTOCOL OUTLINE: This is a multicenter study.
Patients receive acridine carboxamide IV continuously over days 1-5. Treatment repeats every 3 weeks for at least 2 courses and up to a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 weeks until disease progression.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Eligibility
Ages Eligible for Study: 18 Years and above
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
Location Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |